Serotonergic and dopaminergic systems in anorexia nervosa: A role for atypical antipsychotics?

Australian and New Zealand Journal of Psychiatry

Volumn 39, Issue 3, 2005, Pages 146-153

  Bosanac, Peter ^a   Norman, Trevor ^a   Burrows, Graham ^a   Beumont, Peter ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Anorexia nervosa; Antipsychotic; Dopamine; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; ALTANSERIN; AMISULPRIDE; ANTIDEPRESSANT AGENT; APOMORPHINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DEXFENFLURAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; HALOPERIDOL; INSULIN; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; PROLACTIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN 2A ANTAGONIST; SULPIRIDE; TRYPTOPHAN; UNINDEXED DRUG; ZIPRASIDONE;

ANOREXIA NERVOSA; BEHAVIOR THERAPY; BIBLIOGRAPHIC DATABASE; BODY WEIGHT; BODY WEIGHT DISORDER; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; EMBASE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; MEDLINE; MENTAL DISEASE; METABOLIC DISORDER; NERVOUS SYSTEM FUNCTION; NEUROBIOLOGY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; OPEN STUDY; OUTCOMES RESEARCH; PSYCHIATRY; PSYCINFO; QT PROLONGATION; REVIEW; SEROTONINERGIC SYSTEM; SYSTEMATIC REVIEW; WEIGHT GAIN;

ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE; HUMANS; RANDOMIZED CONTROLLED TRIALS; SEROTONIN; TREATMENT OUTCOME;

EID: 15844424547     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1614.2005.01536.x     Document Type: Review

References (106)

1. Beumont PJV, Ben-Tovim D, Touyz S. Eating Disorders. In: Bloch S, Singh BS, eds. Foundations of clinical psychiatry, 2nd edn. Melbourne: Melbourne University Press, 2001; 217-230.
2. Harris EC, Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry 1998; 173:11-53.
3. Theander S. Outcome and prognosis in anorexia nervosa and bulimia: some results of previous investigations compared with those of a Swedish long term study. Journal of Psychiatric Research 1985; 19:493-508.
4. Sullivan PF. Mortality in anorexia nervosa. American Journal of Psychiatry 1995; 152:1073-1074.
5. Herzog DB, Nussbaum KM, Marmor AK. Comorbidity and outcome in eating disorders. Psychiatric Clinics of North America 1996; 19:843-859.
6. Herzog DB, Keller MB, Lavori PW. Outcome in anorexia nervosa and bulimia: a review of the literature. Journal of Nervous and Mental Disease 1988; 176:131-143.
7. Garfinkel PE, Walsh BT. Drug Therapies. In: Garner DM, Garfinkel PE, eds. Handbook of treatment for eating disorders. New York: Guilford, 1997; 372-382.
8. Walters EE, Kendler KS. Anorexia and anorexic-like syndromes in a population-based female twin sample. American Journal of Psychiatry 1995; 152:64-71.
9. Touyz SW, Kopec-Schrader EM, Beumont PJV. Anorexia nervosa in males a report of 12 cases. Australian and New Zealand Journal of Psychiatry 1993; 27:512-517.
10. Andersen AE. Males with eating disorders. New York: Bruner/Mazel, 1990.
11. Lask B, Bryant-Waugh R. Childhood onset of anorexia nervosa and related eating disorders. Hove, UK: Erlbaum, 1993.
12. Cosford P, Arnold E. Eating disorders in later life. International Journal of Geriatric Psychiatry 1992; 7:491-498.
13. Devaud C, Michaud PA, Narring F. Anorexia and bulimia: increasing disorders? A review of the literature on the epidemiology of eating disorders. Revue D Epidemiologie et de Sante Publique 1995; 43:347-360.
14. Eagles JM, Johnston MI, Hunter D, Lobban M, Millar HR. Increasing incidence of anorexia nervosa in the female population of northeast Scotland. American Journal of Psychiatry 1995; 152:1266-1271.
15. Jarman M, Walsh S. Evaluating recovery from anorexia nervosa and bulimia nervosa: integrating lessons learned from research and clinical practice. Clinical Psychology Review 1999; 19:773-788.
16. Ward A, Campbell IC, Brown N, Treasure J. Anorexia nervosa subtypes: differences in recovery. Journal of Nervous and Mental Disease 2003; 191:197-201.
17. Windauer U, Lennerts W, Talbot P, Touyz SW, Beumont PJ. How well are 'cured' anorexia nervosa patients? An investigation of 16 weight-recovered anorexic patients. The British Journal of Psychiatry 1993; 163:195-200.
18. Pike KM. Long-term course of anorexia nervosa: response, relapse, remission, and recovery. Clinical Psychology Review 1998; 18:447-475.
19. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guideline Team for Anorexia Nervosa. Australian and New Zealand clinical practice guidelines for the treatment of anorexia nervosa. Australian and New Zealand Journal of Psychiatry 2004; 38:659-670.
20. Yager J, Andersen A, Devlin M et al. Practice guideline for the treatment of patients with eating disorders, 2nd edn. In: Practice guidelines for the treatment of psychiatric disorders compendium 2002. Washington DC: American Psychiatric Press, 2002; 697-766.
21. Gilchrist P, Ben-Tovim D, Hay PH, Kalucy R, Walker MK. Eating disorders revisited. I: anorexia nervosa. Medical Journal of Australia 1998; 169:438-441.
22. Becker AE, Grinspoon SK, Kiblanski A, Herzog DB. Eating disorders. New England Journal of Medicine 1999; 340:1092-1098.
23. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatrica Scandinavica 2000; 101:416-432.
24. Dally P, Sargant W. A new treatment of anorexia nervosa. British Medical Journal 1960; 1:1770-1773.
25. Dally P, Sargant W. Treatment and outcome of anorexia nervosa. British Medical Journal 1966; 2:793-795.
26. Vandereycken W, Pierloot R. Pimozide combined with behaviour therapy in the short-term treatment of anorexia nervosa: a double-blind placebo-controlled cross-over study. Acta Psychiatrica Scandinavica 1982; 66:445-450.
27. Vandereycken W. Neuroleptics in the short-term treatment of anorexia nervosa. A double-blind placebo-controlled study with sulpiride. British Journal of Psychiatry 1984; 144:288-292.
28. Cassano GB, Miniati M, Pini S et al. Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report. International Journal of Eating Disorders 2003; 33:172-177.
29. Thiel A. Is psychopharmacotherapy necessary in Anorexia and Bulimia Nervosa? Psychotherapie, Psychosomatik Medizinische Psychologie 1997; 47:332-345.
30. Fichter MM. Medication for anorexia and bulimia nervosa: a review. Der Nervenarzt 1993; 64:21-35.
31. Mitchell JE, de Zwaan M, Roerig JL. Drug therapy for patients with eating disorders. Current Drug Targets-CNS and Neurological Disorders 2003; 2:17-29.
32. Strober M. Locus of control, psychopathology, and weight gain in juvenile anorexia nervosa. Journal of Abnormal Child Psychology 1982; 10:97-106.
33. Bruch H. Treatment in anorexia nervosa. International Journal of Psychoanalytic Psychotherapy 1982-1983; 9:303-312.
34. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment the inpatient treatment of anorexia nervosa? American Journal of Psychiatry 1998; 51:548-551.
35. Bergh C, Eriksson M, Lindberg G, Sodersten P. Selective serotonin reuptake inhibitors in anorexia. Lancet 1996; 348:1459-1460.
36. Gwirtsman HE, Guze BH, Yager J, Gainsley B. Fluoxetine treatment of anorexia nervosa: an open clinical trial. Journal of Clinical Psychiatry 1990; 51:378-382.
37. Kaye W, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biological Psychiatry 1998; 44:825-838.
38. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annual Review of Medicine 2001; 52:503-517.
39. Seeman P. Atypical antipsychotics: mechanism of action. Canadian Journal of Psychiatry 2002; 47:27-38.
40. Stahl SM. 'Hit-and-run' actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. Journal of Clinical Psychiatry 2001; 62:670-671.
41. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT (2A) and D (2) receptor blockade increases cortical DA release via 5-HT (1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 2001; 76:1521-1531.
42. Barbarich NC, Kaye WH, Jimerson D. Neurotransmitter and imaging studies in anorexia nervosa: new targets for treatment. Current Drug Targets - CNS and Neurological Disorders 2003; 2:61-72.
43. Binder EB, Kinkead B, Nemeroff CB. Neuropeptides. In: Breier A, Tran PV, Herrera JM, Tollefson GD, Bymaster FP, eds. Current issues in the psychopharmacology of schizophrenia. Philadelphia: Lippincott Williams & Wilkins, 2001; 349-371.
44. Kaye W, Strober M. The neurobiology of eating disorders. In: Charney DS, Nestler EJ, Bunney BS, eds. Neurobiology of mental illness New York: Oxford University Press, 1999; 891-906.
45. Crawley JN. Cholecystokinin-dopamine interactions. Trends in Pharmacological Sciences 1991; 12:232-236.
46. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Canadian Journal of Psychiatry 2002; 47:742-749.
47. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL. Effects of long-term treatment with antipsychotics on serum leptin levels. The British Journal of Psychiatry 2001; 179:59-62.
48. Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. American Journal of Psychiatry 1999; 156:312-314.
49. Leibowitz SF. Differential functions of hypothalamic galanin cell grows in the regulation of eating and body weight. Annals of the New York Academy of Sciences 1998; 863:206-220.
50. Leibowitz SF, Shor-Posner G. Brain serotonin and eating behaviour. Appetite 1986; 7:1-14.
51. Blundell JE. Serotonin and appetite. Neuropharmacology 1984; 23:1537-1551.
52. Wurtman JJ, Wurtman RJ. Drugs that enhance central serotoninergic transmission diminish elective carbohydrate consumption by rats. Life Sciences 1979; 24:895-903
53. Fernstrom JD, Wurtman RJ. Brain serotonin content: increase following ingestion of carbohydrate diet. Science 1971; 174:1023-1025.
54. Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological regulation by plasma neutral amino acids. Science 1971; 178:414-416.
55. Kaye WH, Weltzin TE. Serotonin activity in anorexia and bulimia nervosa relationship to the modulation of feeding and mood. Journal of Clinical Psychiatry 1991; 52(Suppl.):41-48.
56. Cowen PJ, Clifford EM, Walsh AE, Williams C, Fairburn CG. Moderate dieting causes 5-HT2C receptor supersensitivity. Psychological Medicine 1996; 26:1155-1159.
57. Kaye WH, Barbarich NC, Putnam K et al. Anxiolytic effects of acute tryptophan depletion in anorexia nervosa. International Journal of Eating Disorders 2003; 33:257-267.
58. Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995; 20:561-590.
59. Bulik CM, Sullivan PF, Joyce PR, Carter FA. Temperament, character and personality disorder in bulimia nervosa. Journal of Nervous and Mental Disorders 1995; 183:593-572.
60. Deep AL, Nagy LM, Weltzin TE, Rao R, Kaye WH. Premorbid onset of psychopathology in long-term recovered anorexia nervosa. International Journal of Eating Disorders 1995; 17:291-297.
61. Kaye WH, Weltzin TE, Hsu LKG, Bulik CM, McConaha C, Sobkiewicz T. Patients with anorexia nervosa have elevated scores on the Yale-Brown Obsessive-Compulsive Scale. International Journal of Eating Disorders 1992; 12:57-62.
62. Kaye WH, Ebert MH, Raleigh M, Lake R. Abnormalities in CNS monoamine metabolism in anorexia nervosa. Archives of General Psychiatry 1984; 41:350-355.
63. Kaye WH, Gwirtsman HE, George DT, Jimerson DC, Ebert MH. CSF 5-HIAA concentrations in anorexia nervosa: reduced values in underweight subjects normalise after weight gain. Biological Psychiatry 1988; 23:102-105.
64. Kaye WH, Gwirtsman HE, George DT, Ebert MH. Altered serotonin activity in anorexia nervosa after long-term weight restoration: does elevated CSF 5-HIAA correlate with rigid and obsessive behaviour? Archives of General Psychiatry 1991; 48:556-562.
65. Brewerton TD. Towards a united theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995; 20:561-590.
66. Frank GK, Kaye WH, Weltzin TE et al. Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration. International Journal of Eating Disorders 2001; 30:57-68.
67. Brewerton TD, Jimerson DC. Studies of serotonin function in anorexia nervosa. Psychiatry Research 1996; 62:31-42.
68. Monteleone P, Brambilla F, Bortolotti F, La Rocca A, Maj M. Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. The British Journal of Psychiatry 1998; 172:439-442.
69. O'Dwyer AM, Lucey JV, Russell GF. Serotonin activity in anorexia nervosa after long-term weight restoration: response to D-fenfluramine challenge. Psychological Medicine 1996; 26:353-359.
70. Ward A, Brown N, Lightman S, Campbell IC, Treasure J. Neuroendocrine, appetitive and behavioural responses to d-fenfluramine in women recovered from anorexia nervosa. British Journal of Psychiatry 1998; 172:351-358.
71. Fink G, Sumner BEH. Oestrogen and mental state. Nature 1996; 383:306.
72. Garfinkel PE, Lin E, Goering P et al. Should amenorrhoea be necessary for the diagnosis of anorexia nervosa? Evidence from a Canadian community sample. British Journal of Psychiatry 1996; 168:500-506.
73. Frank GK, Kaye WH, Meltzer CC et al. Reduced 5-HT2A receptor binding after recovery from anorexia nervosa. Biological Psychiatry 2002; 52:896-906.
74. Volkow ND, Wang GJ, Fowler JS et al. 'Nonhedonic' food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. Synapse 2002; 44:175-180.
75. Volkow ND, Wang GJ, Maynard L et al. Brain dopamine is associated with eating behaviours in humans. International Journal of Eating Disorders 2003; 33:36-142.
76. Aou S. Physiology of appetite and feeding behaviour: introduction. Japanese Journal of Clinical Medicine 2001; 59:407-412.
77. Kaye WH, Frank GK, McConaha C. Altered dopamine activity after recovery from restricting-type anorexia nervosa. Neuropsychopharmacology 1999; 21:503-506.
78. Barry V, Klavans HL. On the role of dopamine in the pathophysiology of Anorexia Nervosa. Journal of Neural Transmission 1976; 38:107-122.
79. Devesa J, Perez-Fernandez R, Bokser L, Gaudiero GJ, Lima L, Casanueva FF. Adrenal androgen secretion and dopaminergic activity in anorexia nervosa. Hormone and Metabolic Research 1988; 20:57-60.
80. Golden NH, Pepper GM, Sacker I, Avruskin TW. The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls. Journal of Adolescent Health 1992; 13:155-160.
81. Brambilla F, Bellodi L, Arancio C, Ronchi P, Limonta D. Central dopaminergic function in anorexia and bulimia nervosa: a psychoneuroendocrine approach. Psychoneuroendocrinology 2001; 26:393-409.
82. Boachie A, Goldfield GS, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalised children with anorexia nervosa: case reports. International Journal of Eating Disorders 2003; 33:98-103.
83. Bosanac P, Burrows G, Norman T. Olanzapine in anorexia nervosa. Australian and New Zealand Journal of Psychiatry 2003; 37:494.
84. Mehler C, Wewetzer C, Sculze U, Warnke A, Thiesen F, Dittmann RW. Olanzapine in children and adolescents with chronic anorexia nervosa: a study of five cases. European Child and Adolescent Psychiatry 2001; 10:151-157.
85. Ruiz-Lazaro PM, Pueyo A. Use of olanzapine for the treatment of anorexia nervosa in a male adolescent. Revista de Psiquiatria Infanto-Juvenil 2001; 3:29-31.
86. Jensen VS, Mejlhede A. Anorexia nervosa: treatment with olanzapine. British Journal of Psychiatry 2000; 177:87.
87. La Via M, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia nervosa. International Journal of Eating Disorders 2000; 27:363-366.
88. Hansen L. Olanzapine in the treatment of anorexia nervosa. British Journal of Psychiatry 1999; 175:592.
89. Newman-Toker J. Risperidone in anorexia nervosa. Journal of the American Academy of Child and Adolescent Psychiatry 2000; 39:941-942.
90. Conte G, Canmardese G, Cesaro C. Before and during the treatment of two cases of severe anorexia nervosa: the use of an atypical antipsychotic drug. Psicoterapia e Istituzioni: Review of Psychoanalytical Methodological Research and Clinical Experiences 1999; 6:187-190.
91. Fisman S, Steele M, Short J, Byrne T, Lavallee C. Case study: Anorexia nervosa and autistic disorder in an adolescent girl. Journal of the American Academy of Child and Adolescent Psychiatry 1996; 35:937-940.
92. Powers PS, Santana CA, Bannen YS. Olanzapine in the treatment of anorexia nervosa: an open label trial. International Journal of Eating Disorders 2002; 32:146-154.
93. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987; 13:261-276.
94. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960; 23:56.
95. Garner DM. Eating disorder inventory-2: professional manual. Odessa, FL: Psychological Assessment Resources, 1991.
96. Malina A, Gaskill J, McConaha C et al. Olanzapine treatment of anorexia nervosa: a retrospective study. International Journal of Eating Disorders 2003; 33:234-237.
97. Gaskill J, Treat T, McCabe E, Marcus M. Does olanzapine affect the rate of weight gain among inpatients with eating disorders? Eating Disorders Review 2001; 12:1-2.
98. Fairburn CG, Cooper Z. The eating disorders examination (12th edition). In: Fairburn CG, Wilson GT, eds. Binge eating: nature, assessment and treatment. New York: Guilford, 1993; 317-360.
99. Sanavio E. Obsessions and compulsions: the Padua Inventory. Behaviour Research and Therapy 1988; 26:169-177.
100. Montecchi F, Magnani M, Marinucci S, Gambara M, Diamanti A. Risperidone in the control of negative symptoms in anorexia nervosa in adolescents. Minerva Psichiatrica 1998; 39:205-209.
101. Derogatis LR, Cleary PA. Factorial invariance across gender for the primary symptom dimensions of the SCL-90. British Journal of Social and Clinical Psychology 1977; 16:47-356.
102. Bianco G, Claps M, Marinucci S, Montecchi F. Use of risperidone in adolescent anorexia nervosa. Italian Journal of Psychiatry and Behavioural Sciences 2000; 10:50-52.
103. Ruggiero GM, Laini N, Mauri MC et al. A single blind comparison of amisulpride, fluoxetine and clomipramine in the treatment of restricting anorectics. Progress in Neuro-Psychopharmacology and Biology Psychiatry 2001; 25:1049-1059.
104. Keller MB, Lavori PW, Friedman B et al. The longitudinal interval follow-up evaluation. A method for assessing outcome in prospective longitudinal studies. Archives of General Psychiatry 1987; 44:540-548.
105. Geller J. Estimating readiness for change in anorexia nervosa: comparing clients, clinicians, and research assessors. International Journal of Eating Disorders 2002; 31:251-260.
106. Vitousek K, Watson S, Wilson GT. Enhancing motivation for change in treatment-resistant eating disorders. Clinical Psychology Review 1998; 18:391-420.